Two Onc Docs cover image

ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

Two Onc Docs

00:00

Efficacy results: progression‑free survival

Kareen reports the primary endpoint: 24‑month PFS 93.4% with pirtobrutinib versus 70.7% with BR.

Play episode from 06:14
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app